

# Journal Pre-proof

Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF

Cornelius Engelmann, Abeba Habtesion, Mohsin Hassan, Annarein JC. Kerbert, Linda Hammerich, Simone Novelli, Marco Fidaleo, Alexandra Philips, Nathan Davies, Sofia Ferreira-Gonzalez, Stuart J. Forbes, Thomas Berg, Fausto Andreola, Rajiv Jalan



PII: S0168-8278(22)02939-7

DOI: <https://doi.org/10.1016/j.jhep.2022.07.006>

Reference: JHEPAT 8804

To appear in: *Journal of Hepatology*

Received Date: 27 November 2021

Revised Date: 22 May 2022


Accepted Date: 4 July 2022

Please cite this article as: Engelmann C, Habtesion A, Hassan M, Kerbert AJ, Hammerich L, Novelli S, Fidaleo M, Philips A, Davies N, Ferreira-Gonzalez S, Forbes SJ, Berg T, Andreola F, Jalan R, Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF, *Journal of Hepatology* (2022), doi: <https://doi.org/10.1016/j.jhep.2022.07.006>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.

**COMPENSATED CIRRHOSIS**  
**NON-INFLAMMATORY**  
**ENVIRONMENT**



**Title:**

**Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF**

**Authors**

**Cornelius Engelmann<sup>1,2,3,4</sup>, Abeba Habtesion<sup>1</sup>, Mohsin Hassan<sup>3</sup>, Annarein JC Kerbert<sup>1</sup>, Linda Hammerich<sup>3</sup>, Simone Novelli<sup>1,5</sup>, Marco Fidaleo<sup>1,6</sup>, Alexandra Philips<sup>1</sup>, Nathan Davies<sup>1</sup>, Sofia Ferreira-Gonzalez<sup>7</sup>, Stuart J Forbes<sup>7</sup>, Thomas Berg<sup>2</sup>, Fausto Andreola<sup>1§,\*</sup>Rajiv Jalan<sup>1,8§</sup>**

**Affiliations**

<sup>1</sup> Liver Failure Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, United Kingdom

<sup>2</sup> Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany

<sup>3</sup> Medical Department, Division of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Germany

<sup>4</sup> Berlin Institute of Health – Charité – Universitätsmedizin Berlin

<sup>5</sup> Department of Mechanical and Aerospace Engineering, Sapienza University of Rome, Rome, Italy

<sup>6</sup> Department of Biology and Biotechnology "C. Darwin", University of Rome Sapienza, 00185 Rome, Italy.

<sup>7</sup> MRC Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh BioQuarter, 5 Little France Drive, Edinburgh, United Kingdom

<sup>8</sup> European foundation of the study of chronic liver failure, Barcelona, Spain

§Dr Andreola and Prof Jalan are joint senior authors

**\*Corresponding author:**

Prof Rajiv Jalan

Liver Failure Group, Institute for Liver & Digestive Health, Division of Medicine, University

College London UCL, Rowland Hill

Street, London, NW3 2PF, United Kingdom

Phone: +44 02074332795;

E-mail: [r.jalan@ucl.ac.uk](mailto:r.jalan@ucl.ac.uk)

**Competing interests:** Rajiv Jalan has research collaborations with Yaqrif. Rajiv Jalan is the founder of Yaqrif Limited, which is developing UCL inventions for treatment of patients with cirrhosis. Rajiv Jalan is an inventor of ornithine phenylacetate, which was licensed by UCL to Mallinckrodt. He is also a Founder of Hepyx Ltd. and Cyberliver Ltd.

Cornelius Engelmann has received advisory fees from Novartis and CSL Behring. He is shareholder of Hepyx Ltd. Fausto Andreola is shareholder of Hepyx Ltd

Rajiv Jalan, Cornelius Engelmann, Fausto Andreola and Thomas Berg are the named inventors on the patents surrounding the use of G-TAK in ACLF, which have been filed as a priority application. This patent has been licensed to Hepyx Ltd.

**Data and materials availability:** Data are available on request from the corresponding author

**Author contributions:** RJ, TB, FA, CE, FA, ND, SJF - contributed to the conception and design of the study. RJ, ND, FA - provided administrative, study supervision, obtained funding, material support. CE, MF, SFG, FA, AK, SN, LH, MH, AF - performed experiments and substantially contributed to the acquisition of data and its analysis. All authors were involved in the interpretation of data. CE drafted the manuscript. All authors revised the manuscript critically for important intellectual content.

**Funding:** The German Research Foundation (DFG) (EN 1100/2-1) and Berlin Institute of Health (BIH) funded Cornelius Engelmann.

Keywords: liver failure, stem cell therapy, systemic inflammation, regeneration, senescence

Electronic word count: 8469

Number of figures: 6

Number of tables: 0

**Abstract****Background & Aims:**

Acute-on-chronic liver failure (ACLF) is characterised by high short-term mortality, systemic inflammation, and failure of hepatic regeneration. Its treatment is an unmet medical need. This study was conducted to explore whether combining TAK-242, a Toll-like receptor-4 (TLR4) antagonist, with Granulocyte-Colony Stimulating Factor (G-CSF) targets inflammation whilst enhancing liver regeneration.

**Methods:**

Two mouse models of ACLF were investigated. Chronic liver injury was induced by carbon tetrachloride followed by either lipopolysaccharide (LPS) or galactosamine (GalN) as extrahepatic or hepatic insults, respectively. G-CSF and/or TLR4-antagonist, TAK-242, were administered daily. The treatment duration was 24h and 5d in the LPS model and 48h in the GalN model, respectively.

**Results:**

In a LPS-induced ACLF mouse model treatment with G-CSF was associated with a significant mortality of 66% after 48 hours compared with 0% without G-CSF. Addition of TAK-242 to G-CSF abrogated mortality (0%) and significantly reduced liver cell death, macrophage infiltration and inflammation. In the GalN model, both G-CSF and TAK-242, when used individually, reduced liver injury but their combination was significantly more effective. G-CSF treatment, with or without TAK-242, was associated with activation of the pro-regenerative and anti-apoptotic STAT3 pathway. LPS-driven ACLF was characterized by p21 over-expression suggesting hepatic senescence and inhibition of hepatocyte regeneration. While TAK-242 treatment mitigated the effect on senescence, G-CSF, when co-administered with TAK-242, resulted in a significant increase of markers of hepatocyte regeneration.

**Conclusion:**

TLR4 inhibition with TAK-242 rescued G-CSF-driven cell death, inflammation, enhanced tissue repair, and significantly induced regeneration thus suggesting that the combination of G-CSF and TAK-242 is a novel approach for the treatment of ACLF.

(256 words)

**Lay Summary:**

The combinatorial therapy of Granulocyte-Colony Stimulating Factor and TAK-242, a Toll-like Receptor-4 inhibitor, achieves the dual aim of reducing hepatic inflammation and inducing liver regeneration for the treatment of acute-on-chronic liver failure.

## Introduction

Acute-on-chronic liver failure (ACLF) is characterised by multi-organ failure in hospitalised patients with acute decompensation of cirrhosis [1]. The 90-day mortality rates vary from 30-100% depending on the age, number of organ failures and the severity of systemic inflammation. Systemic and hepatic inflammation [2], non-apoptotic cell death [3-5] and a lack of hepatic regeneration [6] are major factors determining the development, course and prognosis of ACLF. Damage-associated molecular patterns (DAMPs) of both nuclear (core histones, HMGB1) and cytoskeletal (cytokeratin 18, K18) origin are released by injured tissues where cell death is prevalent [5, 7, 8]. Furthermore, circulating pathogen-associated molecular patterns (PAMPs), of which lipopolysaccharide (LPS) is a key player [9] are also increased as a result of infections and/or bacterial translocation from the gut into the systemic circulation. Binding of DAMPs and PAMPs to their cognate Pattern Recognition Receptors (PRRs), predominantly Toll-Like Receptor 4 (TLR4), triggers NF- $\kappa$ B-dependent transcription and secretion of pro-inflammatory cytokines such IL1 $\beta$ , IL6 and TNF $\alpha$  leading to a cascade of inflammation and further cell death [8, 10]. Targeted inhibition of TLR4 with a small molecule inhibitor, TAK-242, has been shown to reduce the short-term mortality of animals with ACLF [4] but its administration is associated with reduction in hepatocyte regeneration [11].

Lack of hepatic regeneration is a feature of ACLF and, indeed, hepatocyte proliferation is a positive predictor of survival [12, 13]. Hepatocellular senescence has been hypothesised to inhibit hepatic regeneration in cirrhosis [14] and hepatic inflammation is thought to be the main cause of inhibited cell cycle progression [13, 15]. To modulate hepatic regeneration in ACLF, Granulocyte-Colony Stimulating Factor (G-CSF), which mobilises bone marrow derived stem and immune cells has been studied extensively in patients with ACLF. In several small, underpowered studies in patients with decompensated cirrhosis, alcoholic hepatitis and ACLF, G-CSF was shown to improve survival that was associated with mobilisation of the CD34 $^{+}$  stem cells [16-19]. However, these results could not be reproduced

in a large, placebo controlled multicenter study in Germany [20]. Additionally, about twice the number of G-CSF-treated patients developed ACLF during follow up compared with the placebo group. Moreover, seven serious adverse reactions were observed in the G-CSF-treated group; in five this was related to aggravated organ failure [20]. Previous single-centre trials used various dosing regimens ranging from 5-days to 26-days and doses of 5 µg/kg once daily to 300µg twice daily with similar beneficial results independent of the treatment scheme. The fact that the two multicentre trials covered a similar spectrum with short high dose treatment 15µg/kg once daily [21] and rather low dose 5µg/kg long term therapy [22] speaks against the argument that the lack of efficacy was dose or timing related.

This study was designed to test the hypothesis that the lack of beneficial effect of G-CSF was possibly due to worsening of systemic inflammation through simultaneous release of bone marrow derived inflammatory cells. We further hypothesised that this increased inflammation was through a TLR4-dependent mechanism, as previously shown in a rat model of partial hepatectomy [23]. The aims of this study were to determine whether the addition of TAK-242, a TLR4 antagonist, would prevent G-CSF-related aggravation of liver injury and allow hepatic regeneration. We also aimed to better define the underlying mechanisms of the interplay between G-CSF and TAK-242.

## Material and Methods

### Study design

This study explored the hypothesis in two mouse models of ACLF. All animals were included in the analysis unless specified in the figure legends. Animals were randomly assigned to experimental interventions, but no blinding was applied. All experiments were performed and reported according to the ARRIVE guidelines [24].

### Animal models

All animal experiments were performed in accordance with UK Home Office Animals (Scientific Procedures) Act 1986 (updated 2012) and a project license (No.14378) provided by the UK Home Office. After intervention, animals were monitored closely and prematurely sacrificed if pre-comatose and/or if the disease condition rapidly worsened. Animals in each group were terminated by exsanguination under general anaesthesia with isoflurane (2% isoflurane in oxygen, Piramal Healthcare, USA).

#### *Carbon tetrachloride LPS model*

Male C57BL/6 mice (body weight: 30g±4g; age:8-10 weeks) were gavaged with carbon tetrachloride (CCl<sub>4</sub> 0.5mg/ml dissolved in olive oil – dose 0.5ml/kg bw) twice weekly for a total of 6-weeks to induce liver fibrosis, as described previously [25]. To mimic ACLF, lipopolysaccharide (LPS; *Klebsiella pneumonia*, Sigma, UK), dissolved in saline to a final concentration of 6.25 µg/µl was injected i.p to a final dose of 4mg/kg. Therapeutic interventions with G-CSF (250µg/kg, s.c.) and/or TAK-242 (10mg/kg, i.p.) were started one hour after LPS injection and repeated either 22-hours after LPS injection in the 24hour model or daily in the 5-day model, respectively. Animals were sacrificed 24 hours or 5 days after LPS injections and two hours after the last therapeutic intervention. Time points were chosen based on our previous studies where we observed that there was significant liver injury 24 hours after LPS injection in CCl<sub>4</sub> pre-treated animals [4]. It is also known that liver regeneration and hepatocyte proliferation reaches its maximum earliest 72 hours after injury

with re-established liver mass after 7-days [26] so that the later time was chosen after 5-days.

The study groups were as follows:

1. Vehicle (olive oil, saline) (n=10)
2. CCl<sub>4</sub> (n=10)
3. CCl<sub>4</sub>+G-CSF (5d n=10)
4. CCl<sub>4</sub>+LPS (24h n=10; 5d n=6)
5. CCl<sub>4</sub>+LPS+G-CSF (24h n=10; 5d n=6)
6. CCl<sub>4</sub>+LPS+TAK-242 (24h n=4; 5d n=6)
7. CCl<sub>4</sub>+LPS+TAK-242+G-CSF (24h n=4; 5d n=10)

Vehicle injections were performed with olive oil for CCl<sub>4</sub>, saline for LPS, saline for G-CSF and citric acid/NMP/Captisol for TAK-242.

#### *Carbon tetrachloride - Galactosamine model*

Male C57BL/6 mice (n=8-10 per group) (body weight: 30g±5g; age: 8-10 weeks) were gavaged with carbon tetrachloride (CCl<sub>4</sub> 0.5mg/ml dissolved in olive oil – dose 0.5ml/kg) twice weekly for a total of 6 weeks to induce liver fibrosis. Galactosamine (GalN, Sigma, UK), dissolved in saline, was injected i.p. (1000mg/kg) to induce liver injury. Therapeutic interventions with G-CSF (250µg/kg, s.c.) and/or TAK-242 (10mg/kg, i.p.) were started one hour after GalN injection and repeated after 22 hours and 46 hours post GalN injection. RIPK1 inhibition with RIPA56 (3mg/kg, i.p.) was given 1 hour after GalN and continued twice daily until animals were terminated.

The study groups were as follows:

1. Vehicle (n=10)
2. CCl<sub>4</sub> (n=10)
3. CCl<sub>4</sub>+GalN (n=8)

4. CCl<sub>4</sub>+GalN+RIPA56 (n=8)
5. CCl<sub>4</sub>+GalN+G-CSF (n=8)
6. CCl<sub>4</sub>+GalN+TAK-242 (n=8)
7. CCl<sub>4</sub>+GalN+TAK-242+G-CSF (n=8)

Vehicle injections were performed with olive oil for CCl<sub>4</sub>, saline for GalN, saline for G-CSF and citric acid/NMP/Captisol for TAK-242.

### **Sampling and Storage**

Blood samples were taken from the right heart. Lithium heparin plasma was centrifuged 2500 rpm for 10 min and stored at -80°C for later analysis. All tissues (liver, brain, kidneys) were snap frozen in liquid nitrogen and stored at -80°C for further analysis. In addition, for histological assessments, a sample of the organs was formalin-fixed (10% neutral buffered saline, Leica Biosystems, UK) for 24 hours before paraffin-embedding.

### **Statistical analysis**

The sample size was calculated based on the results provided by Theocharis et al. [27] showing an ALT reduction from 3674 U/L  $\pm$  450 to 2450 U/L  $\pm$  225 after treatment with recombinant G-CSF in mice with thioacetamide (TAA)-induced acute liver failure. We hypothesized conservatively an effect size of 15% in our model with alpha error of 0.05; power of 80% calculating with samples size of 7 animals per group and with a power 90% with sample size of 10 animals per group. The sample size was confirmed by using data from an ACLF rat model of bile duct ligation and LPS injection where LPS injection increased ALT levels to 129.4  $\pm$  33 U/L whilst TAK-242 pre-treatment reduced it to 66.2  $\pm$  9.4 U/L [4]. By using an alpha error of 0.05, we calculated 8 animals per group with a power of 80% and 12 animals per group with a power of 90%. Finally, we aimed at having 10 animals per group unless stated otherwise.

All statistical analyses were performed using SPSS 24 software (SPSS Inc., Chicago; IL). Group comparisons for continuous variables were performed by using Man-Whitney U test and for categorical variables by using Chi-Square test. If more than two groups had to be analysed, one-sided ANOVA with post-hoc Tukey analyses for multiple comparison was used. A p-value  $\leq 0.05$  was considered significant. Graphs were prepared in Prism (GraphPad, USA) and figures compiled in Adobe Photoshop (Adobe Systems, USA).

Further specification on the Material and Methods section can be found in the Supplementary.

## Results

### G-CSF increases the mortality of rodents with ACLF

To understand the pathophysiological basis of the lack of benefit and possible deleterious effect of G-CSF treatment that was observed in the German clinical trial (GRAFT study) [20], we performed pre-clinical studies in murine models of ACLF. In the first model, mice were gavaged for 6-weeks with CCl<sub>4</sub> and then injected with LPS to induce liver injury, as described previously [4, 25] (Fig 1A). 6-weeks CCl<sub>4</sub> administration induced bridging fibrosis (Fig 1D). This model mimics the typical features consisting of multiorgan injury in response to administration of LPS and pre-existing chronic liver injury [4, 25]. 24-hours after LPS injection these animals developed significant liver and kidney injury with high ALT and creatinine levels and extended areas of hepatocyte cell death (TUNEL staining) (Fig 2, Fig S1). Hepatic expression of CCL5, ICAM-1 and NGAL, as markers of inflammation and organ injury, also increased after LPS injection compared to vehicle ( $p<0.001$ ) (Fig. S2) [4]. Liver injury, measured by ALT levels and liver cell death (TUNEL), was decreased 5-days after LPS injection (Fig. S1).

One-hour after LPS injection, mice were treated with G-CSF subcutaneously (250 $\mu$ g/kg) once daily for 5 consecutive days. 24-hours after the first G-CSF injection the number of mobilised CD45<sup>+</sup> cells in the blood increased from a median of 321,900 cells/ml blood (CCl<sub>4</sub>+LPS) to 510,504 cells/ml (CCl<sub>4</sub>+LPS+G-CSF) (Fig 2B). G-CSF therapy led to a mortality of 66% after 48-hours (Fig 1B) and high degree of liver fibrosis (Sirius Red) ( $p<0.001$ , compared to vehicle) (Fig 1D), whereas all other animals without G-CSF treatment survived 5-days follow up. G-CSF administration was associated with increased infiltration of the liver with macrophages [F4/80<sup>+</sup>-DAB positive areas (CCl<sub>4</sub>+LPS) 4.3 %  $\pm$  1.1 vs. 8.4 %  $\pm$  3.9 (CCl<sub>4</sub>+LPS+G-CSF),  $p<0.001$ ] (Fig 1C) after 5-days of G-CSF treatment. Therefore, in this model G-CSF aggravated ACLF-related mortality, which was associated with worsening of hepatic macrophage infiltration.

### TLR4-inhibition by TAK-242 prevents G-CSF related mortality and inflammation

As our previous studies have shown increased hepatocyte TLR4 expression being involved in organ sensitisation to LPS in cirrhosis and a reduction in the severity of inflammation with inhibition of TLR4 in models of ACLF [3], we hypothesised that the deleterious effect of G-CSF in ACLF may be modulated favourably by TLR4 inhibition [28]. We therefore used TAK-242, a small molecule TLR4-inhibitor, with or without G-CSF in the CCl<sub>4</sub> – LPS model over 24-hours and 5-days (Fig 2A).

Administration of TAK-242 together with G-CSF reduced the mortality rate from 66%, in G-CSF treated animals, to 0% (Fig S10). Liver cell death was measured by TUNEL staining 24h after LPS injection. The median relative TUNEL-positive area in liver tissue increased from 0.7% (range 0.2 – 3.3) to 10.1% (range 0.3 – 22.1), which was not significantly different to 7.8% (range 1.6-22.1) observed when G-CSF was injected after LPS. Treatment with TAK-242, alone or in combination with G-CSF, significantly reduced the TUNEL-positive area to 0.19% (range 0.06-0.55, p<0.01) and 0.27% (range 0.16-0.5, p<0.01), respectively (Fig 2C), and reduced ALT levels (Fig 2C). The STAT3 pathway mitigates against apoptosis through release of BCL2, which antagonises BAX. The protective effect of TAK-242/G-CSF was associated with activation of the STAT3 pathway (increased pSTAT3) (Fig S3), possibly induced by IL-22 secretion (Fig S2E), with increased expression of anti-apoptotic BCL2 and higher BCL2/BAX ratio (Fig S3). Likewise, injury markers (such as Lipocalin/NGAL and IL-13) were increased with G-CSF but reduced if TAK-242 was added, as shown by the cytokines / chemokines protein arrays (Fig S2B/C).

Inflammatory response was assessed by measuring liver cytokine expression at both mRNA and protein level. LPS injection led to >4-fold increase in hepatic TNF $\alpha$  mRNA expression, whereas treatment with G-CSF induced an increase in IL-6 mRNA expression level (>2 fold), which was markedly reduced by TAK-242, with or without G-CSF (Fig 2D). G-CSF increased the liver protein expression of inflammatory markers such as CXCL9, LIF and

Petraxin3/TSG-14 as shown by the protein array data from pooled liver lysates. These markers were reduced after TAK-242 injection (Fig S2). TAK-242 treatment resulted in reduced hepatic infiltration of F4/80<sup>+</sup> macrophages [DAB-positive area (%)] – 7.6%±3.6 (CCl<sub>4</sub>+LPS+G-CSF) vs. 2.9%±1.2 (CCl<sub>4</sub>+LPS+G-CSF+TAK-242), (p<0.001)] and Ly6G<sup>+</sup> neutrophils [Ly6G positive cells per bright field – 68.9±1.2 (CCl<sub>4</sub>+LPS+G-CSF) vs. 32.3±12.7 (CCl<sub>4</sub>+LPS+G-CSF+TAK-242), (p<0.05)] (Fig 2F). High numbers of circulating neutrophils and Ly6c-high monocytes occurred in the blood after G-CSF therapy. Their numbers decreased with TAK-242 therapy and the combination of TAK-242 and G-CSF led to an increase of Ly6c-low monocytes (Fig 2E). LPS injection was also associated with stellate cells activation (aSMA expression), which was significantly abrogated by TAK-242 (Fig S4).

Monocytes and macrophages are major sources of cytokine release in liver disease [29]. We therefore tested *in vitro* to what extent LPS, and G-CSF modulate the cytokine response in PMA-activated (*macrophage-like*) and naïve THP1 cells (*monocyte-like*). The experiments showed that G-CSF incubation of PMA-activated THP1 cells and naïve THP1 cells prior to LPS stimulation resulted in aggravated cytokine response, especially up-regulation of IL6 mRNA expression [THP1 *macrophages*+LPS (10ng/mL): 6.2 fold upregulation vs. LPS (10ng/mL)+G-CSF (100ng/mL): 6.7 fold upregulation; THP1 *monocytes*+LPS (10ng/mL): 60.2 fold upregulation vs. LPS(10ng/mL)+G-CSF (100ng/mL): 71 fold upregulation (Fig S5A)]. Results were confirmed in primary PBMCs isolated from healthy donors and incubated with pooled plasma from nine patients with ACLF (Table S3). These cells exhibited a strong upregulation of IL-1b after incubation with G-CSF prior to LPS also in comparison to LPS alone. TAK-242 prevented excess cytokine production in PBMCs with or without G-CSF (Fig. S5B). These *in vitro* findings are in keeping with hepatic IL6 levels, which increased 2.8-fold in G-CSF-treated animals (Fig. 2D). These changes, either with LPS alone or in combination with G-CSF, were completely prevented in the presence of TAK-242 clearly showing that TAK-242 prevents the overwhelming inflammatory response driven by LPS and G-CSF. The

data help to explain the reduction in markers of organ injury in the ACLF animals treated with G-CSF/TAK-242.

**Hepatocellular senescence is a feature of ACLF, which is aggravated by G-CSF but prevented by TAK-242**

Although modulation of inflammation using TAK-242 abrogated the severity of liver injury in the ACLF animals treated with G-CSF and/or LPS, the data does not provide the mechanism underlying failure of regeneration in ACLF. Hepatocellular senescence, an essentially irreversible cell cycle arrest, is a pathophysiological feature of end-stage liver cirrhosis inhibiting regeneration and adequate tissue repair thereby producing poor clinical outcomes [14]. Mediators of cell cycle arrest, such as p16 or p21, are expressed in response to tissue injury and TGFb1 is a key mediator of Senescence-Associated Secretory Phenotype (SASP), where a paracrine spread of injury-independent cellular senescence is observed throughout the liver tissue [30, 31]. We therefore evaluated the effect of LPS and interventions with G-CSF and TAK-242 on markers of senescence.

LPS injection in CCl<sub>4</sub>-treated animals led to a prolonged (up to 5-days post administration) upregulation of both p16 mRNA (1.9-fold compared to vehicles) and TGFb1 in the liver (Western Blot, optical density (OD) vehicle = 0.67 vs. CCl<sub>4</sub>+LPS 24h = 0.99 vs. CCl<sub>4</sub>+LPS 5d = 1.14). Additionally, hepatic protein levels of p21 (Western Blot: OD vehicle=0.33 vs. CCl<sub>4</sub>+LPS 24h=0.8 vs. CCl<sub>4</sub>+LPS 5d=1.14) and Serpin E1/PAI-1 (proteome profiler) (Fig 3A/B; Fig S2C [6]) were also upregulated by LPS indicating the importance of senescence in this model of ACLF. Liver expression of both markers (p21 and Serpin E1/PAI-1) were further exacerbated by G-CSF treatment (p21 Western Blot OD CCl<sub>4</sub>+LPS+G-CSF 24h = 0.97). The administration of TAK-242, with or without G-CSF, effectively mitigated against the expression of all senescence markers (p16, TGFb1, p21 and Serpin E1/PAI-1) (Fig 3A/B; Fig S2C), as shown by mRNA expression (qPCR) and protein expression from pooled liver lysates. p21 immunohistochemistry revealed that activation of the p53/p21 pathway occurred

predominantly in hepatocytes. The number of p21 expressing hepatocytes increased after 24-hours from  $2.8\% \pm 2.2$  with LPS alone to  $8.7\% \pm 3$  with LPS+G-CSF although this effect diminished 5-days after therapy. TAK-242 added to G-CSF significantly reduced the number of p21 expressing (senescent) hepatocytes to  $0.2\% \pm 0.1$ , 24 hours after LPS injection ( $p<0.001$ ) (Fig 3C). Therefore, the data suggest that LPS is a key driver of hepatocellular senescence in ACLF, which is further exacerbated by G-CSF. TLR4 inhibition with TAK-242 prevents this senescent phenotype.

#### **Failure of regeneration in ACLF is synergistically abrogated by G-CSF and TAK-242**

G-CSF has been shown to exhibit regenerative properties in non-inflammatory (not endotoxin-driven) models of liver injury [32, 33]. We therefore hypothesised that the excessive inflammation in ACLF, driven by LPS and/or G-CSF as observed above, may prevent G-CSF to act as pro-regenerative agent and that the addition of TAK-242, which modulates inflammation, may overcome the inhibition of regeneration.

In the CCl<sub>4</sub>-LPS model, therapy with G-CSF for 5-days resulted in hepatocyte activation of Cyclin A2 (Cyclin A2 positive hepatocytes – CCl<sub>4</sub>+LPS  $0.2\% \pm 0.2$  vs. CCl<sub>4</sub>+LPS+G-CSF  $1.4\% \pm 0.7$ ,  $p<0.001$ ) (Fig 4), which is known to mediate cell proliferation by promoting cell cycle progression from S- to M-phase; nevertheless, no induction of proliferation was observed, as indicated by the lack of Ki67 expression (Ki67 positive hepatocytes – CCl<sub>4</sub>+LPS  $0.1\% \pm 0.2$  vs. CCl<sub>4</sub>+LPS+G-CSF  $0.6\% \pm 0.2$ , ns) (Fig 4). However, when G-CSF was given for 5-days in combination with TAK-242 (TAK-242+G-CSF), both markers for cell division significantly increased in hepatocytes [Cyclin A2 hepatocyte expression:  $1.2\% \pm 0.7$  ( $p<0.01$  to TAK-242 single treatment); Ki67 hepatocyte expression  $1.2\% \pm 1$  ( $p<0.05$  to TAK-242 single treatment)] (Fig 4), thus suggesting that TAK-242 enhanced the pro-proliferative effect of G-CSF.

To provide further evidence that G-CSF exhibits a pro-proliferative effect in an environment with lower grade inflammation, we tested 5-days of G-CSF therapy after CCl<sub>4</sub> administration without LPS. In this setting, G-CSF injection significantly increased the number of proliferating hepatocytes; Ki67 staining was observed in 4.1% ± 2.9 (p<0.001 to CCl<sub>4</sub>+LPS+G-CSF 5d) and Cyclin A2 in 2.1% ± 1.3 (p<0.05 to CCl<sub>4</sub>+LPS+G-CSF 5d) (Fig S6).

Protein expression of other regenerative markers was assessed in pooled liver lysates using the proteome array. TAK-242 alone, administered over 24-hours in the CCl<sub>4</sub>-LPS mice, reduced both hepatic markers of vascular regeneration (such as angiopoietin 2, proliferin and PDGF) and other markers involved in liver regeneration, such as IL-22, Flt3-ligand and IGFBP-1 (Fig S2D&E). Adding G-CSF to TAK-242 markedly increased the liver protein expression of these pro-regenerative markers (Fig S2D&E).

To provide more details on the link between inflammation, senescence and regeneration, a multiplex immunofluorescence staining of the liver was performed (Fig 5) including cell type markers (HNF4a – hepatocytes, CK19 – cholangiocytes) as well as Na-K ATPase for cell membrane delineation. After LPS injection and G-CSF treatment, areas of hepatocyte injury (HNF4<sup>+</sup>) indicated by cleaved caspase 3 positivity (p<0.01 compared to CCl<sub>4</sub>+LPS) and macrophage infiltration (Iba1<sup>+</sup>) (p<0.01 compared to CCl<sub>4</sub>+LPS) were surrounded by □H2AX expressing hepatocytes, which are associated with senescence. The combination of TAK-242 and G-CSF abrogated liver injury (cleaved caspase 3 - p<0.001 when comparing CCl<sub>4</sub>+LPS+G-CSF with CCl<sub>4</sub>+LPS+G-CSF+TAK-242) and reduced inflammatory infiltration/response (Iba1 – p<0.01 comparison between CCl<sub>4</sub>+LPS+G-CSF and CCl<sub>4</sub>+LPS+G-CSF+TAK-242). Therapy with TAK-242 and G-CSF resulted in a decrease of senescent hepatocytes (□H2Ax – p<0.01 comparison between CCl<sub>4</sub>+LPS+G-CSF and CCl<sub>4</sub>+LPS+G-CSF+TAK-242) whilst hepatocyte expression of proliferation markers PCNA (p<0.001 comparison between CCl<sub>4</sub>+LPS and CCl<sub>4</sub>+LPS+G-CSF+TAK-242) and Ki67

( $p<0.001$  comparison between  $\text{CCl}_4+\text{LPS}+\text{G-CSF}$  and  $\text{CCl}_4+\text{LPS}+\text{G-CSF+TAK-242}$ ) was promoted predominantly in the periportal region (Fig 5).

These findings support the hypothesis that G-CSF requires an environment with reduced inflammation to exert its proliferative effects on hepatocytes and, therefore, TAK-242 allows G-CSF to unfold its pro-regenerative capacities.

#### **TAK-242/G-CSF reduces tissue injury in $\text{CCl}_4$ – GaIN treated mice**

The effect of G-CSF, with or without TAK-242, was then tested in a second model where galactosamine (GaIN), instead of LPS, was used as sterile toxic insult in mice treated for 6-weeks with  $\text{CCl}_4$  (Fig 6).

First, we explored the extent of liver injury induced by GaIN on the background of  $\text{CCl}_4$  and how this was modulated by G-CSF  $\pm$  TAK-242. GaIN injection induced a significant liver injury with high ALT levels [27.3 U/L (range 24.2–63.4) vs. 288 U/L (range 46-807)], extended areas of cell death (TUNEL) [0.23% (range 0.17-0.29) vs. 2.6% (range 1.3-5.2)], and RIPK3 positivity [1% (range 0.75-1.1) vs. 3.2% (range 1.6-4.4)], a marker for necroptotic cell death. In contrast to the inflammatory LPS model, treatment with G-CSF alone reduced ALT levels [101 U/L (range 51-284),  $p<0.05$ ], liver cell death (TUNEL 1.2% (range 0.4-1.9),  $p<0.001$ ) and RIPK3 expression [1.9% (range 0.9-2.5),  $p<0.001$ ]. TAK-242 alone reduced ALT levels to 96.5 U/L [(range 45-229),  $p<0.05$ ], RIPK3 expression [1.7% (range 0.9-2.1),  $p<0.001$ ] and liver cell death (TUNEL) [1.4% (range 0.4-3.3),  $p<0.001$ ], however without reaching statistical significance. The combination of G-CSF and TAK242 was superior to both single treatments and improved ALT levels to 74.5 U/L (range 44-297), liver cell death (TUNEL) [0.45% (0.11-0.95),  $p<0.001$  compared with TAK-242 and  $p<0.01$  compared with G-CSF] and RIPK3 expression [1.23% (1-1.78),  $p<0.001$  to  $\text{CCl}_4+\text{GaIN}$ ] (Fig 6B). Furthermore, treatment with TAK-242 + G-CSF was also associated with activation of the STAT3 pathway

and a trend to increased anti-apoptotic BCL2 expression as assessed in pooled liver samples by Western Blot (Fig 6C).

We also evaluated whether hepatocyte proliferation was modulated by treatment with G-CSF  $\pm$  TAK-242 in this model. CCl<sub>4</sub>-treated animals injected with GaIN showed high levels of proliferating hepatocytes [Ki67: CCl<sub>4</sub> 0.1%  $\pm$  0.1 vs. CCl<sub>4</sub> + GaIN 2%  $\pm$  1.7; Cyclin A2: CCl<sub>4</sub> 0.1%  $\pm$  0.2 vs. CCl<sub>4</sub> + GaIN 1.9%  $\pm$  1.6] and hepatocytes in cell cycle arrest (p21: CCl<sub>4</sub> 0.5%  $\pm$  0.2 vs. CCl<sub>4</sub> + GaIN 6.4%  $\pm$  4.7). Treatment with G-CSF, with or without TAK-242, reduced the degree of proliferating and senescent hepatocytes, whereas TAK-242 alone did not alter the response to injury [(Ki67: CCl<sub>4</sub>+GaIN+TAK-242 - 3%  $\pm$  2.1 vs. CCl<sub>4</sub>+GaIN+TAK-242+G-CSF: 1.2%  $\pm$  1.4 (p<0.01); Cyclin A2: CCl<sub>4</sub>+GaIN+TAK-242 - 1.9%  $\pm$  1.6 vs. CCl<sub>4</sub>+GaIN+TAK-242+G-CSF 0.3%  $\pm$  0.2 (p<0.001); p21: CCl<sub>4</sub>+GaIN+TAK-242 - 7.1%  $\pm$  4.5 vs. CCl<sub>4</sub>+GaIN+TAK-242+G-CSF - 1.7%  $\pm$  2.3 (p<0.001)] (Fig 6D).

Taken together these data suggest that in this model with low grade inflammation, the combination of G-CSF and TAK-242 impacts positively on liver injury, regeneration and reduces markers of senescence. It also confirms that the regenerative effect of G-CSF is preserved in an environment with reduced inflammation.

### **Relationship between cell death and liver regeneration and the effect of G-CSF and TAK-242**

To explore the role of cell death as a modulator and inducer of regeneration, we used RIPA56, a selective RIPK1 inhibitor, to prevent GaIN-induced necroptotic cell death in the different groups of animals with CCl<sub>4</sub>-induced chronic liver injury. RIPA56 treatment effectively prevented GaIN-driven cell death [Total cell death ((TUNEL p<0.001) and necroptosis (RIPK3 p<0.001), both compared to CCl<sub>4</sub>+GaIN] and was associated with a decrease in hepatocyte proliferation compared to CCl<sub>4</sub>+GaIN (Ki67 2%  $\pm$  1.7 vs. 0.2%  $\pm$  0.2, p<0.001; Cyclin A2 1.9%  $\pm$  1.6 vs. 0.03%  $\pm$  0.1, p<0.001), (Fig S7), which suggests that in

this environment with low grade inflammation, the regenerative response correlates directly with the severity of liver injury, as previously observed [30].

We then calculated the ratio between expression of Cyclin A2, as a marker of cell cycle progression, and the severity of total liver cell death (TUNEL) to delineate the pro-regenerative capacity in relation to liver injury of both drugs in all models studied; an increase in the ratio Cyclin A2/TUNEL would represent enhanced regenerative activity with less cell death and vice versa (Fig S8). In the 24-hour  $\text{CCl}_4$ -LPS model, LPS completely inhibited regenerative responses (CyclinA2/TUNEL ratio:  $\text{CCl}_4$ : 0.42;  $\text{CCl}_4$ +LPS: 0.02;  $\text{CCl}_4$ +LPS+G-CSF: 0.04), with or without G-CSF. In contrast, in the  $\text{CCl}_4$ -GalN model the regenerative response was preserved (CyclinA2/TUNEL ratio:  $\text{CCl}_4$ +GalN 0.54). In both “short-term” models, administration of TAK-242 was associated with enhanced liver cell regenerative response (CyclinA2/TUNEL ratio:  $\text{CCl}_4$ +LPS+TAK-242: 1.4;  $\text{CCl}_4$ +GalN+TAK-242: 0.9) supporting the hypothesis that creating an ‘inflammation-free’ environment is important to restore regenerative capacities, as also described recently in a model of  $\text{CCl}_4$  and *Klebsiella pneumonia*-induced ACLF model [15]. Moreover, the anti-inflammatory environment (in presence of TAK-242) allowed G-CSF to unfold its positive effect on liver injury, notably in the  $\text{CCl}_4$ -LPS model, and to enhance regeneration after 5-days of therapy (CyclinA2/TUNEL ratio:  $\text{CCl}_4$ + LPS+TAK-242+G-CSF: 1.7), thus supporting the pro-regenerative capacity of G-CSF especially after long-term treatment.

## Discussion

The results of this study provide novel insights into the mechanisms underlying the molecular pathogenesis of ACLF focusing on the relationship between inflammation and regeneration. The data provide the rationale for combining G-CSF, a recombinant protein that mobilises stem cells from the bone marrow, and a TLR4 inhibitor, TAK-242, that has been shown in animal models of ACLF to reduce hepatic inflammation and mortality. Here we show for the first time that in models of LPS- or GaIN-induced ACLF, G-CSF and TAK-242 act in combination to improve the severity of liver injury that is associated with modulation of inflammation, reduction in cellular senescence and improved regeneration.

ACLF has a dismal prognosis [34], and its treatment is an unmet need. In ACLF, TLR4-driven inflammation and lack of hepatic regeneration determines the disease course [4, 12, 15, 35]. Additionally, danger associated molecular patterns (DAMPs [36] released from non-apoptotic, immunogenic forms of cell death (such as necroptosis), and pathogen associated molecular patterns (PAMPs) [3, 4] derived from infection and/or intestinal bacterial translocation both initiate a cascade of cytokine-driven inflammatory responses that underlie the pathogenesis of the syndrome in which the TLR4 pathway plays an important role [4, 5, 8]. This systemic inflammation is also associated with the release of endogenous G-CSF, which can induce further tissue injury [2, 35]. Paradoxically, G-CSF has been used to treat ACLF patients with a view to mobilise the bone marrow stem cell with variable results [18, 19, 21]. Although preclinical studies suggested that G-CSF may help in tissue repair [27], and some clinical trials in ACLF patients showed promising results [18], the large multicentre randomised clinical trial of G-CSF failed to show a beneficial effect. In fact, in the subgroup of patients with the most severe inflammation, there were some suggestions that G-CSF may even be deleterious [20].

In a rat model of septic liver injury, 4-day pre-treatment with G-CSF resulted in increased liver expression of LPS-binding protein (LPB) and TLR4. Administration of LPS to these

animals led to enhanced liver cell death and mortality showing a negative sensitising effect of G-CSF [28]. However, in human trials, administration of G-CSF to treat sepsis showed no evidence of efficacy but G-CSF did not induce any excess mortality. It is important to note that these patients had no underlying liver disease [37]. When rats were treated with G-CSF in a rodent model of partial (70%) hepatectomy, administration of LPS was associated with severe liver injury and excess mortality compared with partial hepatectomy and LPS injection alone [23]. These results indicate that G-CSF may sensitise the liver to LPS through TLR4, which may be deleterious in ACLF patients as these patients present with high levels of circulating DAMPs and PAMPs, potent ligands for this receptor [5, 9]. To better understand the mechanisms underlying the potential deleterious effect of G-CSF, we used murine models of ACLF that mimic the human phenotype. Administration of LPS to mice with advanced fibrosis led to ACLF [4, 25], which was associated with severe inflammation, liver injury, hepatocellular senescence, and high mortality rate. G-CSF exaggerated the inflammatory response and further induced cell death by decreasing BCL2/BAX ratio favouring cell death. Inhibiting the TLR4 receptor signalling with TAK-242, which was associated with marked reduction in the severity of systemic and hepatic inflammation, prevented the increased mortality with G-CSF. Furthermore, TAK-242 allowed G-CSF to act through activation of the STAT3 pathway preventing further cell death by releasing BCL2 and inducing hepatocyte proliferation. These observations may indicate that the combination may indeed be synergistic in their action rather than simply additive. It may be argued that true recovery needs to be proven at multiple levels, which may be true especially for hepatotoxic injuries in acute liver injury. However, ACLF comprises a complex pathogenesis including inflammation, cell death and inadequate regeneration with predominance of one or the other in different disease stages. We observed that the combinatorial therapy addresses all aspects and preserves tissue integrity exhibited by low ALT levels and 100% survival. G-CSF may also target side effects of TAK-242, which may impair response to pathogens such as phagocytosis increasing the risk of secondary infections [38]. However, TAK-242 did not increase the risk of infections in human trials and was shown to be safe in sepsis [39].

Nevertheless, any future trial will need to monitor closely for infections when patients are treated with a TLR4 antagonist.

ACLF is characterised by a lack of regeneration and LPS-driven inflammation is potentially of pathogenic importance [15]. In the LPS-precipitated model of ACLF, the number of Ki67<sup>+</sup> hepatocytes were markedly reduced despite activation of Cyclin A2. This may be related to the inhibitory effect of hepatocellular senescence on hepatic regeneration, indicated by increased hepatocellular p21 expression. In human liver tissues of patients with ACLF, the presence of infiltrating CD68<sup>+</sup> macrophages was associated with low numbers of proliferating hepatocytes [6] and in a ACLF mouse model, infection was an important determinant of inhibition of regeneration [15]. Taken together, the data support the hypothesis that targeting inflammation may improve regeneration.

The relationship between TLR4 signalling and cell proliferation is contradictory; previous *in vitro* work on tumour cell lines indicated a pro-proliferative effect on malignant parenchymal cells [40-42], whereas TLR4 stimulation by LPS was proposed by others to halt the ability for cell division in pluripotent progenitor cells [43, 44]. In cirrhotic animals, administration of LPS inhibited regeneration, as evidenced by activation of the IFNy-STAT1 pathway with increased expression of cyclin-dependent kinase complex inhibitor while reducing the expression of Cyclin D1. Additionally, administration of G-CSF to LPS-induced ACLF animals led to markedly increased expression of p21 in the hepatocytes, which was associated with enhanced expression of other senescence mediators such as Serpin1E, p16 and TGFb1. TLR4 signalling also leads to TGFb1 release, which is a classical SASP mediator, activating p21 independently of p53 [30, 31]. Taken together, senescence is an important consequence of LPS-induced ACLF, which is aggravated by G-CSF. These data allow us to hypothesise that senescence and concomitant inflammatory environment may be involved in the inhibition of hepatic regeneration in ACLF. The observation that inhibiting the TLR4 pathway with TAK-242 in both the LPS-induced ACLF and the G-CSF-treated animals with reduced markers of

hepatic inflammation and senescence but enhanced hepatic regeneration provides evidence for the importance of the role of senescence in hepatic regeneration. Evidence for the co-existence of pathogen/endotoxin driven inflammation and lack of regeneration is robust and alcoholic hepatitis, one of the leading precipitating events for ACLF seems to be one of the potential indications for treatment with this combinatorial therapy. Dubuquoy et al. indicated that livers from patients with alcoholic hepatitis lack sufficient hepatocyte proliferation whilst showing increased proliferation of hepatic progenitor cells and ductular reaction [12]. The same disease is also characterised by high levels of circulating LPS and inflammation [9].

To further validate our observations and determine whether this pro-regenerative effect could be reproduced in an environment of non-LPS-driven, sterile injury, we created a new model of ACLF using GaIN on the background of advanced fibrosis. We confirmed similar effects of the combination therapy also in this model. Although G-CSF alone reduced tissue injury, its effect on tissue repair, when combining it with TAK-242, was superior to the individual treatments. This observation shows that TAK-242 overcomes the effect of injury-related release of DAMPs and TLR4 activation confirming the beneficial effect of the combination therapy even when the superimposed injury is non-LPS related.

This study is limited by the fact that ACLF is a heterogeneous entity and animal models might mimic only part of the disease spectrum. However, using an inflammatory and a sterile model of ACLF mimicking extrahepatic and hepatic insults, allows to both explore the major pathogenic factors involved in disease development and progression. Although our study provides important insight into the inflammation-senescence-regeneration sequence and provides a potential novel therapeutic strategy, further research is needed to understand the involvement of endothelial cells and other subsets of immune cells (such as macrophages), which might modulate regenerative responses; their involvement is likely as indicated in this study by changes in the markers of vascular regeneration, such as angiopoietin, proliferin and platelet-derived growth factor (PDGF), possibly also acting through modulation of TGFb1

expression [45, 46]. It may be also necessary to apply the combinatorial therapy in models where infection induces ACLF [15] and models of alcoholic hepatitis to test the G-TAK in models mimicking the most frequent precipitating events. The models applied here targeting mechanistic aspect of pathogenetic changes, which occur throughout the whole spectrum of ACLF therefore being the basis for translation into humans and for future mechanistic studies.

Although the clinical course of ACLF is not confounded by the gender, mechanistic preclinical studies should include ideally both, male and female animals. Here we chose to use male animals only because the model applied in this study was previously developed in male animals.

In conclusion, the results of this study provide new evidence for the importance of the LPS-TLR4 pathway in modulating the systemic and hepatic inflammation that is associated with ACLF and its role in inducing hepatocyte senescence and inhibiting regeneration in ACLF. We report the novel observation that the combinatorial therapy of TLR4 inhibition using TAK-242 and G-CSF reduces liver injury and improves hepatocyte proliferation through reduction in inflammation and senescence. This overcomes the inhibition of hepatic regeneration, a characteristic feature of ACLF. As both drugs are known to be safe, they can be repurposed and evaluated in combination in patients with ACLF.

**Acknowledgement:**

We would like to thank Alexander Hettich for creating the graphical abstract.

**Bibliography**

1. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013;144:1426-1437, 1437 e1421-1429.
2. Claria J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, Amoros A, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. *Hepatology* 2016;64:1249-1264.
3. Engelmann C, Adebayo D, Oria M, De Chiara F, Novelli S, Habtesion A, Davies N, et al. Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure. *Sci Rep* 2020;10:389.
4. Engelmann C, Sheikh M, Sharma S, Kondo T, Loeffler-Wirth H, Zheng YB, Novelli S, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. *J Hepatol* 2020;73:102-112.
5. Macdonald S, Andreola F, Bachtiger P, Amoros A, Pavesi M, Mookerjee R, Zheng YB, et al. Cell death markers in patients with cirrhosis and acute decompensation. *Hepatology* 2018;67:989-1002.
6. Shubham S, Kumar D, Rooge S, Maras JS, Maheshwari D, Nautiyal N, Kumari R, et al. Cellular and functional loss of liver endothelial cells correlates with poor hepatocyte regeneration in acute-on-chronic liver failure. *Hepatol Int* 2019;13:777-787.
7. Adebayo D, Morabito V, Andreola F, Pieri G, Luong TV, Dhillon A, Mookerjee R, et al. Mechanism of cell death in acute-on-chronic liver failure: a clinico-pathologic-biomarker study. *Liver Int* 2015;35:2564-2574.

8. Engelmann C, Claria J, Szabo G, Bosch J, Bernardi M. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. *J Hepatol* 2021;75 Suppl 1:S49-S66.
9. Michelena J, Altamirano J, Abraldes JG, Affo S, Morales-Ibanez O, Sancho-Bru P, Dominguez M, et al. Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. *Hepatology* 2015;62:762-772.
10. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. *J Hepatol* 2014;61:1385-1396.
11. Kashani B, Zandi Z, Bashash D, Zaghal A, Momeny M, Poursani EM, Pourbagheri-Sigaroodi A, et al. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid). *Cancer Chemother Pharmacol* 2020;85:47-59.
12. Dubuquoy L, Louvet A, Lassailly G, Truant S, Boleslawski E, Artru F, Maggiotto F, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. *Gut* 2015;64:1949-1960.
13. Engelmann C, Mehta G, Tacke F. Regeneration in acute-on-chronic liver failure - the phantom lost its camouflage. *J Hepatol* 2020.
14. Sen B, Rastogi A, Nath R, Shasthry SM, Pamecha V, Pandey S, Gupta KJ, et al. Senescent Hepatocytes in Decompensated Liver Show Reduced UPR(MT) and Its Key Player, CLPP, Attenuates Senescence In Vitro. *Cell Mol Gastroenterol Hepatol* 2019;8:73-94.
15. Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, Matyas C, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming of impaired regeneration pathways in mice. *J Hepatol* 2019.
16. Kedarisetty CK, Anand L, Bhardwaj A, Bhadaria AS, Kumar G, Vyas AK, David P, et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves

outcomes of patients with decompensated cirrhosis. *Gastroenterology* 2015;148:1362-1370 e1367.

17. Singh V, Sharma AK, Narasimhan RL, Bhalla A, Sharma N, Sharma R. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. *Am J Gastroenterol* 2014;109:1417-1423.
18. Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, Sakhija P, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. *Gastroenterology* 2012;142:505-512 e501.
19. Engelmann C, Martino VD, Kerbert AJC, Weil-Verhoeven D, Aehling NF, Herber A, Thevenot T, et al. The Current Status of Granulocyte-Colony Stimulating Factor to Treat Acute-on-Chronic Liver Failure. *Semin Liver Dis* 2021;41:298-307.
20. Engelmann C, Herber A, Franke A, Bruns T, Schiefke I, Zipprich A, Zeuzem S, et al. Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). *J Hepatol* 2021;S0168-8278(21)01963-2:Online ahead of print.
21. Newsome PN, Fox R, King AL, Barton D, Than NN, Moore J, Corbett C, et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. *Lancet Gastroenterol Hepatol* 2018;3:25-36.
22. Engelmann C, Herber A, Franke A, Bruns T, Reuken P, Schiefke I, Zipprich A, et al. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). *J Hepatol* 2021;75:1346-1354.
23. Liu A, Fang H, Wei W, Kan C, Xie C, Dahmen U, Dirsch O. G-CSF pretreatment aggravates LPS-associated microcirculatory dysfunction and acute liver injury after partial hepatectomy in rats. *Histochem Cell Biol* 2014;142:667-676.

24. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. *PLoS Biol* 2020;18:e3000410.

25. Carl DE, Ghosh SS, Gehr TW, Abbate A, Toldo S, Sanyal AJ. A model of acute kidney injury in mice with cirrhosis and infection. *Liver Int* 2016;36:865-873.

26. Michalopoulos GK. Liver regeneration. *J Cell Physiol* 2007;213:286-300.

27. Theocharis SE, Papadimitriou LJ, Retsou ZP, Margeli AP, Ninos SS, Papadimitriou JD. Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy. *Dig Dis Sci* 2003;48:1797-1803.

28. Fang H, Liu A, Sun J, Kitz A, Dirsch O, Dahmen U. Granulocyte colony stimulating factor induces lipopolysaccharide (LPS) sensitization via upregulation of LPS binding protein in rat. *PLoS One* 2013;8:e56654.

29. Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. *Nat Rev Immunol* 2017;17:306-321.

30. Bird TG, Muller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadarramas E, Lu WY, et al. TGFbeta inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. *Sci Transl Med* 2018;10.

31. Ferreira-Gonzalez S, Lu WY, Raven A, Dwyer B, Man TY, O'Duibhir E, Lewis PJS, et al. Paracrine cellular senescence exacerbates biliary injury and impairs regeneration. *Nat Commun* 2018;9:1020.

32. Piscaglia AC, Shupe TD, Oh SH, Gasbarrini A, Petersen BE. Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. *Gastroenterology* 2007;133:619-631.

33. Tsolaki E, Athanasiou E, Gounari E, Zogas N, Siotou E, Yiannou M, Anagnostopoulos A, et al. Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic

stem cell mobilization agents reverse induced chronic liver injury. *Blood Cells Mol Dis* 2014;53:124-132.

34. Engelmann C, Thomsen KL, Zakeri N, Sheikh M, Agarwal B, Jalan R, Mookerjee RP. Validation of CLIF-C ACLF score to define a threshold for futility of intensive care support for patients with acute-on-chronic liver failure. *Crit Care* 2018;22:254.
35. Arroyo V, Moreau R, Jalan R, Gines P, Study E-CCC. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. *J Hepatol* 2015;62:S131-143.
36. Soffientini U, Beaton N, Baweja S, Weiss E, Bihari C, Habtesion A, Patel V, et al. The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury. *Front Cell Dev Biol* 2021;9:668459.
37. Wunderink R, Leeper K, Jr., Schein R, Nelson S, DeBoisblanc B, Fotheringham N, Logan E. Filgrastim in patients with pneumonia and severe sepsis or septic shock. *Chest* 2001;119:523-529.
38. Lv J, He X, Wang H, Wang Z, Kelly GT, Wang X, Chen Y, et al. TLR4-NOX2 axis regulates the phagocytosis and killing of *Mycobacterium tuberculosis* by macrophages. *BMC Pulm Med* 2017;17:194.
39. Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. *Crit Care Med* 2010;38:1685-1694.
40. Jiang N, Xie F, Guo Q, Li MQ, Xiao J, Sui L. Toll-like receptor 4 promotes proliferation and apoptosis resistance in human papillomavirus-related cervical cancer cells through the Toll-like receptor 4/nuclear factor-kappaB pathway. *Tumour Biol* 2017;39:1010428317710586.
41. Zu Y, Ping W, Deng T, Zhang N, Fu X, Sun W. Lipopolysaccharide-induced toll-like receptor 4 signaling in esophageal squamous cell carcinoma promotes tumor proliferation and regulates inflammatory cytokines expression. *Dis Esophagus* 2017;30:1-8.

42. Yue Y, Zhou T, Gao Y, Zhang Z, Li L, Liu L, Shi W, et al. High mobility group box 1/toll-like receptor 4/myeloid differentiation factor 88 signaling promotes progression of gastric cancer. *Tumour Biol* 2017;39:1010428317694312.

43. Shechter R, Ronen A, Rolls A, London A, Bakalash S, Young MJ, Schwartz M. Toll-like receptor 4 restricts retinal progenitor cell proliferation. *J Cell Biol* 2008;183:393-400.

44. Feng X, Feng G, Xing J, Shen B, Tan W, Huang D, Lu X, et al. Repeated lipopolysaccharide stimulation promotes cellular senescence in human dental pulp stem cells (DPSCs). *Cell Tissue Res* 2014;356:369-380.

45. Hu J, Srivastava K, Wieland M, Runge A, Mogler C, Besemfelder E, Terhardt D, et al. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. *Science* 2014;343:416-419.

46. Starlinger P, Assinger A. Importance of platelet-derived growth factors in liver regeneration. *Expert Rev Gastroenterol Hepatol* 2016;10:557-559.

**Figure Legends:****Figure 1: Effect of G-CSF in an ACLF mouse model**

A) Animals were gavaged for 6-weeks with 0.5ml/ml Carbon tetrachloride ( $CCl_4$ ) to induce chronic liver injury. Thereafter, LPS (*Klebsiella pneumoniae*) was injected to induce multi-organ injury. G-CSF (250 $\mu$ g/kg, s.c.) was injected one hour after LPS and continued for 5-days once daily (Vehicle n=10,  $CCl_4$  n=10,  $CCl_4$  + LPS n=6,  $CCl_4$  + LPS + G-CSF n=6).

B) In total, 66% of all animals died in the group treated with G-CSF alone. Survival in the other groups was 100%.

C) 5-days of G-CSF treatment increased hepatic macrophage infiltration ( $F4/80^+$ ) compared to animals with  $CCl_4$ +LPS only ( $p<0.001$ ).

D) This ACLF model was associated with significant collagen accumulation (Sirius Red staining,  $p<0.001$  compared to vehicle) after 5-days  $CCl_4$ .

$CCl_4$  - Carbon tetrachloride; G-CSF – granulocyte-colony stimulating factor.

Group comparison was performed by one-way ANOVA and post-hoc Tukey's multiple comparison.

**Figure 2: TAK-242 prevents the deleterious effect of G-CSF in the  $CCl_4$ -LPS model.**

A) C57B/6 mice were gavaged for 6-weeks with carbon tetrachloride ( $CCl_4$ ) 0.5mg/ml to induce chronic liver injury. Thereafter, LPS (*Klebsiella pneumoniae*) was injected to induce multi-organ injury. G-CSF (250 $\mu$ g/kg, s.c.) was injected 1-hour after LPS and continued for 24-hours or 5-days once daily. TAK-242 was administered concurrently (10mg/kg, i.p.) and continued once daily for 24-hours or 5-days.

B) G-CSF injection led to an increase of  $CD45^+$  circulating haematopoietic cells (n=4 per group)

C) TAK-242 reduced LPS-driven liver cell death (TUNEL) ( $p<0.01$ ) (n=4 per group) and ALT levels (all animals per group).

D) LPS injection increased liver TNFa mRNA expression (>2 fold), whereas the additional G-CSF treatment led to an overexpression of IL-6 mRNA (>2 fold). Expression of both cytokines was reduced after injection of TAK-242 (n=4 per group)

E) G-CSF treatment after LPS injection led to high numbers of circulating neutrophils and Ly6c-high activated monocytes. TAK-242 reduced the number of both cell subsets and promoted the occurrence of Ly6c-low monocytes in the blood (flow cytometry) (n=4 per group=

F) TAK-242 decreased the amount of liver infiltrating F4/80<sup>+</sup> macrophages (p<0.001) and Ly6G<sup>+</sup> neutrophils (p<0.05) (n=4 per group).

Image J was used for image quantification and group comparison was performed by one-way ANOVA and post-hoc Tukey's multiple comparison only among the following groups: CCl<sub>4</sub>+LPS, CCl<sub>4</sub>+LPS+G-CSF, CCl<sub>4</sub>+LPS+TAK-242, CCl<sub>4</sub>+LPS+G-CSF+TAK-242. mRNA data is delineated as □ Ct value. Western blots were performed with protein lysates pooled from all animals per group.

**Figure 3: Evidence of hepatocellular senescence in the rodent model of ACLF and the effect of G-CSF and TAK-242.**

A) Increased hepatic p16 mRNA expression in CCl<sub>4</sub> + LPS animals with or without treatment with G-CSF treatment, after 24-hours and 5-days. TLR4 inhibition with TAK-242 effectively reduced p16 mRNA expression at both time points (n=4 per group).

B) Increased hepatic protein expression of p21 and TGFb1 in CCl<sub>4</sub>+LPS animals with or without treatment with G-CSF treatment, after 24-hours and 5-days. The optical density (OD – Western Blot liver lysates) increased from vehicle = 0.67 to CCl<sub>4</sub>+LPS 24h = 0.99 and CCl<sub>4</sub> + LPS 5d = 1.14. Hepatic protein levels of p21 were raised starting from vehicle = 0.33 to CCl<sub>4</sub>+LPS 24h = 0.8 and CCl<sub>4</sub>+LPS 5d = 1.14. G-CSF exaggerated TGFb1 (OD 1.1) and p21 expression (OD 0.97) 24-hours after LPS injection. TLR4 inhibition with TAK-242 effectively reduced protein expression of p21 and TGFb1 at both time points (all individuals per group).

Western Blot was repeated twice and one representative blot shown here.

C) Liver immunohistochemistry demonstrated that p21 expression occurred predominantly in hepatocytes and could be prevented by TAK-242, with or without G-CSF (n=3 per group). 24-hours after LPS injection,  $2.8\% \pm 2.2$  hepatocytes expressed p21, which was enhanced by adding G-CSF to  $8.7\% \pm 3$ . This effect diminished 5-days after therapy. TAK-242 added to G-CSF significantly reduced the number of p21 expressing (senescent) hepatocytes to  $0.2\% \pm 0.1$ , 24-hours after LPS injection ( $p<0.001$ ).

Image J was used for image quantification and group comparison was performed by one-way ANOVA and post-hoc Tukey's multiple comparison only among the following groups:  $CCl_4+LPS$ ,  $CCl_4+LPS+G-CSF$ ,  $CCl_4+LPS+TAK-242$ ,  $CCl_4+LPS+G-CSF+TAK-242$ . mRNA data is delineated as  $\Delta\Delta Ct$  value and a greater than 2-fold change in expression was considered as biologically relevant. Western blots were performed with protein lysates pooled from all animals per group.

**Figure 4: Evidence for induction of regeneration markers in hepatocytes induced by TAK-242/G-CSF**

Immunofluorescence and histochemistry staining for Cyclin A2 and Ki67, mediators of cell cycle progression, in paraffin embedded liver tissue (n=3 per group) (Cyclin A2 upper panel, Ki67 lower panel). In the 24-hr treatment model, G-CSF increased Cyclin A2-expressing hepatocytes (Cyclin A2 positive hepatocytes –  $CCl_4+LPS$ :  $0.2\% \pm 0.2$  vs.  $CCl_4+LPS+G-CSF$ :  $1.4\% \pm 0.7$ ). TAK-242 decreased Cyclin A2 positive cells without reaching significance. In the 5-day treatment model, G-CSF alone and in combination with TAK-242, significantly stimulated expression of Cyclin A2 ( $0.6\% \pm 0.5$  vs.  $1.2\% \pm 0.7$  ( $p<0.001$ ) and Ki67 [ $0.6\% \pm 0.3$  vs.  $1.2\% \pm 1$  ( $p<0.05$ )] in hepatocytes also in comparison to TAK-242 alone. Hepatocyte proliferation was also stimulated by G-CSF, 24-hrs after LPS injection ( $p<0.05$  to  $CCl_4+LPS$ ).

Image J was used for image quantification and group comparison was performed by one-way ANOVA and post-hoc Tukey's multiple comparison only among the following groups:  $CCl_4+LPS$ ,  $CCl_4+LPS+G-CSF$ ,  $CCl_4+LPS+TAK-242$ ,  $CCl_4+LPS+G-CSF+TAK-242$ .

**Figure 5: Multiplex staining of liver tissue depicts localisation of injury, senescence and proliferation after G-CSF and TAK-242 in the CCl<sub>4</sub> – LPS model**

Multiplex immunofluorescence staining on one exemplary sample per group was performed to understand the regional interaction between tissue injury, inflammation and regenerative response. Tissues were sequentially stained for HNF4a (hepatocytes), CK19 (cholangiocytes), Na-K-ATPase (cell membrane), cleaved caspase 3 (cell death/injury), RIPK3 (necroptosis), γH2AX (senescence), Iba1 (macrophage), Cyclin A2 and Ki67 (cell cycle progression). After CCl<sub>4</sub>+LPS+G-CSF there were extended areas of injury with macrophage infiltration and high numbers of senescent and non-proliferating hepatocytes. After abrogation of tissue injury and reduced number of macrophages by TAK-242 and G-CSF there was an increase of proliferating hepatocytes, predominantly in the periportal region. Image processing was performed by *l*lastik and *CellProfiler* was used for quantification. Group comparison was performed by one-way ANOVA and post-hoc Tukey's multiple comparison only among the following groups: CCl<sub>4</sub>+LPS, CCl<sub>4</sub>+LPS+G-CSF, CCl<sub>4</sub>+LPS+TAK-242, CCl<sub>4</sub>+LPS+G-CSF+TAK-242.  $p>0.05$  was considered statistically significant.

**Figure 6: Effect of TAK-242/G-CSF in an ACLF model with low-grade inflammation**

A) C57B/6 mice were gavaged for 6-weeks with carbon tetrachloride (CCl<sub>4</sub>) 0.5mg/ml to induce chronic liver injury ( $n=8$  per group). Thereafter, galactosamine (GalN) was injected to induce a sterile liver injury. G-CSF (250μg/kg, s.c.) was injected first one hour after GalN and continued for 48-hours. TAK-242 was given concurrently (10mg/kg, i.p.) and continued once daily for 48-hours.

B) GalN injection induced a liver injury with high ALT levels [288 U/L (range 46-807)], cell death (TUNEL) [2.6% (range 1.3-5.2)] and RIPK3 expression (necroptosis) [3.2% (range 1.6-4.4),  $p<0.001$ ]. Liver injury was reduced by all treatment options but the combination therapy, TAK-242+G-CSF, was superior to the single compounds (ALT levels 74.5 U/L

(range 44-297), ns; (TUNEL 0.45% (0.11-0.95),  $p<0.001$  compared to TAK-242 and  $p<0.01$  compared to G-CSF); RIPK3 expression (1.23% (1-1.78),  $p<0.001$  to  $CCl_4+GalN$ )

C) The treatment effect was associated with activation of the STAT3 pathway and a trend to increased anti-apoptotic BCL2 expression as shown by Western Blot in pooled samples. Western Blot was repeated twice and one representative blot shown here

D) GalN induced a regenerative response with proliferating hepatocytes [Ki67:  $CCl_4$  0.1%  $\pm$  0.1 vs.  $CCl_4 + GalN$  2%  $\pm$  1.7, Cyclin A2:  $CCl_4$  0.1%  $\pm$  0.2 vs.  $CCl_4+GalN$  1.9%  $\pm$  1.6] but also hepatocytes in cell cycle arrest [p21:  $CCl_4$  0.5%  $\pm$  0.2 vs.  $CCl_4+GalN$  6.4%  $\pm$  4.7]. G-CSF alone or in combination with TAK-242 reduced cell death and the subsequent regenerative response. TAK-242 alone maintained the amount of proliferating (Cyclin A2, Ki67) and senescent (p21) hepatocytes [(Ki67  $CCl_4+GalN+TAK-242$  3%  $\pm$  2.1 vs.  $CCl_4+GalN+TAK-242+G-CSF$  1.2%  $\pm$  1.4 ( $p<0.01$ ); Cyclin A2  $CCl_4+GalN+TAK-242$  1.9%  $\pm$  1.6 vs.  $CCl_4+GalN+TAK-242+G-CSF$  0.3%  $\pm$  0.2 ( $p<0.001$ ); p21  $CCl_4+GalN+TAK-242$  7.1%  $\pm$  4.5 vs.  $CCl_4+GalN+TAK-242+G-CSF$  1.7%  $\pm$  2.3 ( $p<0.001$ )].

Image J was used for image quantification and group comparison was performed by one-way ANOVA and post-hoc Tukey's multiple comparison only among the following groups:  $CCl_4+LPS$ ,  $CCl_4+LPS+G-CSF$ ,  $CCl_4+LPS+TAK-242$ ,  $CCl_4+LPS+G-CSF+TAK-242$ . mRNA data is delineated as  $\Delta\Delta Ct$  value and a greater than 2-fold change in expression was regarded as biologically significant. Western blots were performed with protein lysates pooled from all animals per group.

#### Abbreviations:

ACLF – Acute-on-chronic liver failure

ALT – Alanine aminotransferase

aSMA – Alpha smooth muscle antigen

BAX – BCL2 associated X protein

BCA – Bicinchoninic acid

BCL2 – B-cell lymphoma 2 protein

CCl<sub>4</sub> – Carbontetrachloride

CCL5 – CC-chemokine ligand 5

CK19 – Cytokeratin 19

CXCL9 – CXC-ligand 9

DAMP – Damage-associated molecular pattern

DAB – Diaminobenzidine

DAPI – Diamidino-2-phenylindole

FACS – Fluorescence activated cell sorting

FFPE – Formalin-fixated paraffin embedded

FITC –Fluorescein-5-isothiocyanate

Flt3 – FMS-like tyrosine kinase 3

GalN – Galactosamine

GAPDH – Glycerinaldehyd-3-phosphat-dehydrogenase

G-CSF – Granulocyte-colony stimulating factor

H2Ax – phosphorylated H2A histone family member X

HMGB1 – High-mobility group box 1

HNF4a – Hepatocyte nuclear factor 4 alpha

HRP – Horseradish peroxidase

ICAM-1 – Intercellular adhesion molecule 1

ICC – Immunocytochemistry

IL – Interleukine

IGFBP-1 – Insuline-like growth factor-binding protein 1

IHC – Immunohistochemistry

LIF – Leukemia inhibitory factor

LPS – Lipopolysaccharide

MPER – Mammalian protein extraction reagent

Na-K ATPase – Sodium-potassium ATPase

NGAL – Neutrophil gelatinase-associated lipocalin

OD – Optical density

PAI-1 – Plasminogen activator inhibitor-1

PAMP – Pathogen-associated molecular pattern

PBMC – Peripheral blood mononuclear cells

PBS – Phosphate buffered saline

PDGF – Platelet-derived growth factor

PMA – Phorbol 12-myristate-13-acetate

PRR – Pattern recognition receptor

RBC – Red blood cells

RIPK1 – Receptor-interacting serine/threonine-protein kinase 1

SASP – Senescence-associated secretory phenotype

STAT3 – Signal transducer and activator of transcription 3

TAA – Thioacetamide



TBS-T – Tris-buffered saline with tween

TLR4 – Toll-like receptor 4

TNF $\alpha$  – Tumor necrosis factor alpha



TSG-14 – Tumor necrosis factor-stimulated gene 14

TUNEL – Terminal deoxynucleotidyl transferase biotin-dUTP nick end labelling





C


### Hepatic macrophage infiltration (immunohistochemistry)




D

### Sirius Red staining liver







## B - Cell mobilisation CD45+ve cell blood




## C - Liver injury







## D - Cytokine expression liver




## E - Immune cell subsets blood (flow cytometry)



## F - Immune cell subsets liver (immunohistochemistry)




### A - p16 mRNA expression liver



### B - Protein expression liver

#### Journal Pre-proof



1 - Vehicle  
2 - CCl4

4h treatment

3 - CCl4+LPS  
4 - CCl4+LPS+G-CSF

5 - CCl4+LPS+TAK-242

6 - CCl4+LPS+TAK-242 +G-CSF

LPS - 5d treatment




7 - CCl4+LPS

8 - CCl4+LPS+G-CSF


9 - CCl4+LPS+TAK-242

10 - CCl4+LPS+TAK-242 +G-CSF


### C - p21 expression liver (immunohistochemistry)









### p21




### CCl4+LPS+TAK-242 +G-CSF 24h




Cyclin A2 - LPS model  
24 hours treatmentCyclin A2 - LPS model  
5 days treatmentKi67 - LPS model  
24 hours treatmentKi67 - LPS model  
5 days treatment



D








## ALT level GaIN model

B

## Journal Pre-proof

TUNEL liver tissue  
GaIN model


n&lt;0.001

RIPK3 liver tissue  
GaIN model

C


## GaIN model

1 2 3 4 5 6




- 1 - Vehicle
- 2 - CCl4
- 3 - CCl4+GaIN
- 4 - CCl4+GaIN+G-CSF
- 5 - CCl4+GaIN+TAK-242
- 6 - CCl4+GaIN+TAK-242+G-CSF

## pSTAT3/STAT3 ratio



## BCL2/BAX ratio




D

## CCl4+GaIN

## CCl4+GaIN +G-CSF

## CCl4+GaIN +TAK-242




## CCl4+GaIN +TAK-242+G-CSF



## Cyclin A2 hepatocytes

## Ki67 hepatocytes

## p21 hepatocytes



**Highlights:**

- G-CSF alone increases mortality and promotes inflammation in rodent models of ACLF.
- The combination of TLR4 inhibition and G-CSF inhibits inflammation, promotes hepatic regeneration and prevents mortality in models of ACLF.